Correlation analysis between CXC chemokine receptor 6 and prognosis of renal clear cell carcinoma

Q4 Medicine

肿瘤研究与临床 Pub Date : 2019-12-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2019.12.007

Xin Ma, Yuanyi Wen, Yong Wang, M. Zhang, Fujun Liu

{"title":"Correlation analysis between CXC chemokine receptor 6 and prognosis of renal clear cell carcinoma","authors":"Xin Ma, Yuanyi Wen, Yong Wang, M. Zhang, Fujun Liu","doi":"10.3760/CMA.J.ISSN.1006-9801.2019.12.007","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the correlation between CXC chemokine receptor 6 (CXCR6) and prognosis of renal clear cell carcinoma. \n \n \nMethods \nA total of 100 patients with renal clear cell carcinoma who underwent surgery in the First People's Hospital of Ziyang from January 2013 to October 2014 were selected. Immunohistochemistry was used to detect the expression of CXCR6 in 100 cases of renal clear cell carcinoma and adjacent normal tissues. The patients were followed up to observe the positive rate of CXCR6 expression and the factors affecting overall survival (OS) and progression-free survival (PFS) of renal clear cell carcinoma and adjacent normal tissues. \n \n \nResults \nThe positive rate of CXCR6 expression in renal clear cell carcinoma tissues was higher than that in adjacent tissues, and the difference was statistically significant [46.0% (46/100) vs. 20.0% (20/100), χ2 = 15.287, P < 0.01]. The positive expression rate of CXCR6 in patients with clinical stage Ⅲ-Ⅳ, lymph node metastasis and pathological grade Ⅲ-Ⅳ was higher than that in patients with clinical stage Ⅰ- Ⅱ, pathological grade Ⅰ- Ⅱ and without lymph node metastasis, and the difference was statistically significant (all P < 0.05). A total of 92 patients were followed up and 40 died. The follow-up time reached to (35-60) months and the median follow-up time was 48.9 months. Kaplan-Meier and log-rank test showed that patients with positive CXCR6 expression had lower 3-year OS and PFS rate compared with patients with negative CXCR6 expression, and the difference was statistically significant (3-year OS rate: 52.1% vs. 78.6%, χ2 = 10.027, P = 0.001; 3-year PFS rate: 48.3% vs. 67.8%, χ2 = 4.344, P = 0.037). Cox regression multivariate analysis showed pathological grade (OS: OR = 2.154, 95% CI 1.547-9.517, P = 0.023; PFS: OR = 1.235, 95% CI 1.109-5.917, P = 0.042), lymph node metastasis (OS: OR = 1.412, 95% CI 1.109-5.917, P = 0.041; PFS: OR = 1.841, 95% CI 1.354-8.994, P = 0.010), CXCR6 expression (OS: OR = 1.864, 95% CI 1.358-6.813, P = 0.031; PFS: OR = 1.457, 95% CI 1.127-6.884,P = 0.025) were independent risk factors of OS and PFS for renal clear cell carcinoma patients treated by the surgery. \n \n \nConclusions \nThe positive expression of CXCR6 is an independent risk factor for OS and PFS of renal clear cell carcinoma. The prognosis of patients with positive CXCR6 expression is poor. \n \n \nKey words: \nCarcinoma, renal cell; Receptors, chemokine; Prognosis","PeriodicalId":9505,"journal":{"name":"肿瘤研究与临床","volume":"31 1","pages":"823-827"},"PeriodicalIF":0.0000,"publicationDate":"2019-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"肿瘤研究与临床","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1006-9801.2019.12.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective To investigate the correlation between CXC chemokine receptor 6 (CXCR6) and prognosis of renal clear cell carcinoma. Methods A total of 100 patients with renal clear cell carcinoma who underwent surgery in the First People's Hospital of Ziyang from January 2013 to October 2014 were selected. Immunohistochemistry was used to detect the expression of CXCR6 in 100 cases of renal clear cell carcinoma and adjacent normal tissues. The patients were followed up to observe the positive rate of CXCR6 expression and the factors affecting overall survival (OS) and progression-free survival (PFS) of renal clear cell carcinoma and adjacent normal tissues. Results The positive rate of CXCR6 expression in renal clear cell carcinoma tissues was higher than that in adjacent tissues, and the difference was statistically significant [46.0% (46/100) vs. 20.0% (20/100), χ2 = 15.287, P < 0.01]. The positive expression rate of CXCR6 in patients with clinical stage Ⅲ-Ⅳ, lymph node metastasis and pathological grade Ⅲ-Ⅳ was higher than that in patients with clinical stage Ⅰ- Ⅱ, pathological grade Ⅰ- Ⅱ and without lymph node metastasis, and the difference was statistically significant (all P < 0.05). A total of 92 patients were followed up and 40 died. The follow-up time reached to (35-60) months and the median follow-up time was 48.9 months. Kaplan-Meier and log-rank test showed that patients with positive CXCR6 expression had lower 3-year OS and PFS rate compared with patients with negative CXCR6 expression, and the difference was statistically significant (3-year OS rate: 52.1% vs. 78.6%, χ2 = 10.027, P = 0.001; 3-year PFS rate: 48.3% vs. 67.8%, χ2 = 4.344, P = 0.037). Cox regression multivariate analysis showed pathological grade (OS: OR = 2.154, 95% CI 1.547-9.517, P = 0.023; PFS: OR = 1.235, 95% CI 1.109-5.917, P = 0.042), lymph node metastasis (OS: OR = 1.412, 95% CI 1.109-5.917, P = 0.041; PFS: OR = 1.841, 95% CI 1.354-8.994, P = 0.010), CXCR6 expression (OS: OR = 1.864, 95% CI 1.358-6.813, P = 0.031; PFS: OR = 1.457, 95% CI 1.127-6.884,P = 0.025) were independent risk factors of OS and PFS for renal clear cell carcinoma patients treated by the surgery. Conclusions The positive expression of CXCR6 is an independent risk factor for OS and PFS of renal clear cell carcinoma. The prognosis of patients with positive CXCR6 expression is poor. Key words: Carcinoma, renal cell; Receptors, chemokine; Prognosis

查看原文本刊更多论文

CXC趋化因子受体6与肾透明细胞癌预后的相关性分析

目的探讨肾透明细胞癌CXC趋化因子受体6 (CXCR6)与预后的关系。应用免疫组化方法检测CXCR6在100例肾透明细胞癌及邻近正常组织中的表达。对患者进行随访，观察CXCR6表达阳性率及影响肾透明细胞癌及邻近正常组织总生存期(OS)和无进展生存期(PFS)的因素。结果肾透明细胞癌组织中CXCR6表达阳性率高于癌旁组织，差异有统计学意义[46.0%(46/100)比20.0% (20/100)，χ2 = 15.287, P < 0.01]。临床分期Ⅲ-Ⅳ、淋巴结转移及病理分级Ⅲ-Ⅳ患者中CXCR6阳性表达率高于临床分期Ⅰ-Ⅱ、病理分级Ⅰ-Ⅱ及无淋巴结转移患者，差异均有统计学意义(P < 0.05)。随访92例，死亡40例。随访时间35 ~ 60个月，中位随访时间48.9个月。Kaplan-Meier和log-rank检验显示，CXCR6表达阳性患者的3年OS和PFS率低于CXCR6表达阴性患者，差异有统计学意义(3年OS率:52.1%比78.6%，χ2 = 10.027, P = 0.001;3年PFS率:48.3%比67.8%，χ2 = 4.344, P = 0.037)。Cox回归多因素分析显示病理分级(OS: OR = 2.154, 95% CI 1.547 ~ 9.517, P = 0.023;PFS: OR = 1.235, 95% CI 1.109-5.917, P = 0.042)，淋巴结转移(OS: OR = 1.412, 95% CI 1.109-5.917, P = 0.041;PFS: OR = 1.841, 95% CI 1.354-8.994, P = 0.010)， CXCR6表达(OS: OR = 1.864, 95% CI 1.358-6.813, P = 0.031;PFS: OR = 1.457, 95% CI 1.127 ~ 6.884,P = 0.025)是手术治疗肾透明细胞癌患者OS和PFS的独立危险因素。结论CXCR6阳性表达是肾透明细胞癌OS和PFS的独立危险因素。CXCR6阳性表达的患者预后较差。关键词:癌;肾细胞;趋化因子受体;预后

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.